Literature DB >> 31362994

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Anne Boel1, Anna Molto2, Désirée van der Heijde3, Adrian Ciurea4, Maxime Dougados2,5, Lianne S Gensler6, Maria-José Santos7, Eugenio De Miguel8, Denis Poddubnyy9,10, Martin Rudwaleit11, Astrid van Tubergen12,13, Floris A van Gaalen3, Sofia Ramiro3,14.   

Abstract

BACKGROUND: Patients with spondyloarthritis with radiographic sacroiliitis are traditionally classified according to the modified New York (mNY) criteria as ankylosing spondylitis (AS) and more recently according to the Assessment of SpondyloArthritis international Society (ASAS) criteria as radiographic axial spondyloarthritis (r-axSpA).
OBJECTIVE: To investigate the agreement between the mNY criteria for AS and the ASAS criteria for r-axSpA and reasons for disagreement.
METHODS: Patients with back pain ≥3 months diagnosed as axSpA with radiographic sacroiliitis (mNY radiographic criterion) were selected from eight cohorts (ASAS, Esperanza, GESPIC, OASIS, Reuma.pt, SCQM, SPACE, UCSF). Subsequently, we calculated the percentage of patients who fulfilled the ASAS r-axSpA criteria within the group of patients who fulfilled the mNY criteria and vice versa in six cohorts with complete information.
RESULTS: Of the 3882 patients fulfilling the mNY criteria, 93% also fulfilled the ASAS r-axSpA criteria. Inversely, of the 3434 patients fulfilling the ASAS r-axSpA criteria, 96% also fulfilled the mNY criteria. The main cause for discrepancy between the two criteria sets was the reported age at onset of back pain.
CONCLUSION: Almost all patients with axSpA with radiographic sacroiliitis fulfil both ASAS and mNY criteria, which supports the interchangeable use of the terms AS and r-axSpA. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ankylosing spondylitis; epidemiology; outcomes research; spondyloarthritis

Mesh:

Year:  2019        PMID: 31362994     DOI: 10.1136/annrheumdis-2019-215707

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

Review 1.  Understanding the paradigm of non-radiographic axial spondyloarthritis.

Authors:  Diego Benavent; Victoria Navarro-Compán
Journal:  Clin Rheumatol       Date:  2020-09-29       Impact factor: 2.980

Review 2.  Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.

Authors:  Hanan Al Rayes; Mansour Alazmi; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi; Suzan Attar
Journal:  Clin Rheumatol       Date:  2022-01-08       Impact factor: 2.980

Review 3.  Use of Imaging in Axial Spondyloarthritis for Diagnosis and Assessment of Disease Remission in the Year 2022.

Authors:  Ann-Sophie De Craemer; Zuzanna Łukasik; Philippe Carron
Journal:  Curr Rheumatol Rep       Date:  2022-10-15       Impact factor: 4.686

Review 4.  Axial Spondyloarthritis in Japan.

Authors:  Hideto Kameda; Mitsumasa Kishimoto; Shigeto Kobayashi; Tetsuya Tomita; Akimichi Morita; Masahiro Yamamura
Journal:  Curr Rheumatol Rep       Date:  2022-04-05       Impact factor: 4.686

Review 5.  Treat-to-target in axial spondyloarthritis - what about physical function and activity?

Authors:  Jürgen Braun; Xenofon Baraliakos; Uta Kiltz
Journal:  Nat Rev Rheumatol       Date:  2021-07-26       Impact factor: 20.543

6.  Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study.

Authors:  Jean W Liew; John D Reveille; Maria Castillo; Henna Sawhney; Benjamin S Naovarat; Susan R Heckbert; Lianne S Gensler
Journal:  J Rheumatol       Date:  2020-07-01       Impact factor: 4.666

Review 7.  Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis.

Authors:  Runsheng Wang; Joan M Bathon; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2020-02-24       Impact factor: 15.483

8.  Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.

Authors:  Walter P Maksymowych; Mikkel Østergaard; Robert Landewé; William Barchuk; Ke Liu; Leen Gilles; Thijs Hendrikx; Robin Besuyen; Xenofon Baraliakos
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

Review 9.  Work Disability in Axial Spondyloarthritis.

Authors:  Elena Nikiphorou; Sofia Ramiro
Journal:  Curr Rheumatol Rep       Date:  2020-07-27       Impact factor: 4.592

10.  Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort.

Authors:  Monika Hebeisen; Raphael Micheroli; Almut Scherer; Xenofon Baraliakos; Manouk de Hooge; Désirée van der Heijde; Robert Landewé; Kristina Bürki; Michael J Nissen; Burkhard Möller; Pascal Zufferey; Pascale Exer; Adrian Ciurea
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.